COLL vs SUPN: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

SUPN is the larger of the two ($6.07B market cap): the incumbent the market prices for continued execution (7.29x forward earnings, beta 1.13). COLL is the smaller challenger ($777.20M), cheaper on forward earnings (3.53x): more room to run, but more to prove. If you believe in growth, SUPN fits: analysts expect its revenue to rise 8% next year, against 2% for COLL. If you believe in paying less for profit, COLL fits: it trades at 3.53x forward earnings, against 7.29x for SUPN.

COLL vs SUPN: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricCOLLSUPNWhat it tells you
Market cap$777.20M$6.07BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E3.537.29Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta0.731.13Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range12% of range19% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.

Reading it: COLL is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how COLL and SUPN affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. COLL and SUPN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined COLL and SUPN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Collegium Pharmaceutical (COLL) do?

Collegium Pharmaceutical, based in Stoughton, Massachusetts, sells branded prescription drugs in the US. It does not discover new molecules; it buys approved brands and runs them with its own sales force. The pain portfolio covers Belbuca (buprenorphine buccal film), Xtampza ER (abuse-deterrent extended-release oxycodone) and the Nucynta franchise (tapentadol). The ADHD side came through two deals: the 2024 purchase of Ironshore, which brought Jornay PM, an evening-dosed methylphenidate, and the May 2026 purchase of Azstarys (serdexmethylphenidate and dexmethylphenidate) from Corium for about $656 million in cash plus up to $135 million in milestones.

Full COLL guide

What does Supernus Pharmaceuticals (SUPN) do?

Supernus Pharmaceuticals develops and sells prescription medicines for central nervous system conditions: ADHD, epilepsy, Parkinson's disease and, more recently, postpartum depression. The commercial model is straightforward specialty pharma. Supernus owns or licenses the products, runs its own US sales force calling on neurologists and psychiatrists, and books the revenue net of rebates and channel discounts. Its growth engine is Qelbree, a non-stimulant ADHD treatment that did ~$89 million in net sales in the second quarter of 2026 (up ~15%), alongside GOCOVRI for Parkinson's dyskinesia (~$38 million), ONAPGO, a continuous subcutaneous apomorphine infusion launched in 2025 (~$14 million), and collaboration revenue from ZURZUVAE for postpartum depression (~$35 million), which Supernus acquired when it bought Sage Therapeutics in mid-2025 and which it splits 50/50 with Biogen. Working against that are the legacy products: Trokendi XR and Oxtellar XR each fell ~25% year over year, APOKYN fell ~51%, and other older products fell ~71%.

Full SUPN guide

COLL vs SUPN: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • COLL drivers: Jornay PM share gains in ADHD; Azstarys as a second ADHD brand.
  • SUPN drivers: Qelbree as the volume anchor in ADHD; ONAPGO and the device-delivered Parkinson's franchise.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The largest risk is the pace of pain-portfolio decline. For SUPN, the legacy portfolio is shrinking faster than it looks on a consolidated line: Trokendi XR and Oxtellar XR are guided to only ~$50 million to ~$60 million combined for 2026, APOKYN halved year over year and took a ~$55 million impairment, and every dollar lost there has to be replaced before growth shows up in total revenue.

COLL or SUPN: which should you pick?

If the story you believe is COLL's (Jornay PM share gains in ADHD), COLL is the more direct way to own it; if it is SUPN's (Qelbree as the volume anchor in ADHD), SUPN is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the COLL and SUPN guides.

COLL vs SUPN: the full fundamentals

COLL. Figures combine the fourth quarter of 2025 with the first nine months of 2026, at a share price of about $25.03 on November 20, 2026 and about 31.1 million shares outstanding. Adjusted figures exclude large non-cash items, mainly about $55 million a quarter of amortization on acquired drug rights, which is why GAAP diluted EPS for the first nine months of 2026 was only about $0.64 and the trailing GAAP P/E is near 23. A multiple near 3 times adjusted earnings is low for a profitable drug company and shows how much the market discounts the pain brands. The $239 million of convertible notes convert at about $36.56 a share, well above the current price.

SUPN. At ~$29.18 the combined Supernus trades at ~4.4 times trailing sales, ~5.4 times EV/EBITDA and ~7 times consensus 2027 earnings, a low multiple for a business with an ~86% gross margin. The discount reflects SUBLOCADE concentration, legacy-product decay and new leverage, and the trailing GAAP per-share figures are muddied by merger accounting. Until the first full combined quarter is reported, the forward estimates carry more weight than the trailing numbers.

Headline figures (approximate, November 2026): COLL shows revenue (ttm) ~$815 million (+3.3% YoY in Q3), q3 2026 adjusted eps $1.96 vs ~$1.86 consensus, adjusted ebitda (ttm) ~$467 million, adjusted eps (ttm) ~$7.67; SUPN shows revenue (ttm, yahoo basis, indivior before the close) ~$1.37B; latest quarter up ~13% year over year, q3 2026 (indivior standalone, quarter to september 30) ~$356M revenue, ~$137M net income; EPS ~$1.32 vs ~$1.13 estimate, margins (ttm) ~86% gross, ~47% operating, ~33% net, consensus revenue ~$2.26B for 2026, ~$2.45B for 2027.

The bottom line: COLL vs SUPN

COLL and SUPN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined COLL and SUPN exposure against your real portfolio. It is not an investment adviser.

Wondering how COLL or SUPN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Collegium Pharmaceutical

Ask Walnut's AI anything about COLL and see how it fits what you own.

FAQ

What is the difference between COLL and SUPN?

+

Collegium Pharmaceutical, based in Stoughton, Massachusetts, sells branded prescription drugs in the US. Supernus Pharmaceuticals develops and sells prescription medicines for central nervous system conditions: ADHD, epilepsy, Parkinson's disease and, more recently, postpartum depression. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is COLL or SUPN the better stock?

+

Neither is universally better. SUPN is the larger incumbent; COLL is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, COLL or SUPN?

+

On forward P/E (as of November 2026), COLL trades at 3.53x and SUPN at 7.29x, so COLL is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both COLL and SUPN?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of COLL vs SUPN?

+

COLL: The largest risk is the pace of pain-portfolio decline. Nucynta revenue fell 44% in a year once generics arrived, and a 2018 settlement allows Teva to sell a generic Belbuca from January 23, 2027 if it has FDA approval. Belbuca was about $222 million of 2025 revenue, so a launch would cut deeply into cash flow. Ascent Pharmaceuticals has also filed to challenge Belbuca's 2032 patent. Xtampza ER faces payer pressure. Opioid exposure brings legal risk: several dozen third-party payors sued Collegium and others in July 2026, alleging Nucynta and Xtampza ER were promoted to encourage continued prescribing, and several state attorneys general have open investigations. ADHD stimulants are Schedule II drugs, so DEA production quotas and shortages can limit supply. The balance sheet carries about $1.08 billion of debt plus a Jornay royalty obligation at about 13.5% effective interest, and cash fell from about $387 million at the end of 2025 to $145 million after the Azstarys purchase. Operating expenses rose 44% in the third quarter, and further acquisitions add integration risk. The stock is small and has been volatile, falling about 17% after the August report and about 45% so far in 2026. Analysts expect revenue of about $848 million in 2027 but adjusted EPS to fall about 5% to roughly $7.08, which reflects the Belbuca generic risk. SUPN: The legacy portfolio is shrinking faster than it looks on a consolidated line: Trokendi XR and Oxtellar XR are guided to only ~$50 million to ~$60 million combined for 2026, APOKYN halved year over year and took a ~$55 million impairment, and every dollar lost there has to be replaced before growth shows up in total revenue. Qelbree's US new-chemical-entity exclusivity ran out in April 2026 and Supernus received Paragraph IV notices from multiple generic filers in 2025, so the patents running from 2029 to 2035 now have to be defended in court rather than assumed. The merger closed on November 2, 2026, so the execution risk has moved to integration: the combined company carries leverage from the pre-closing special dividend, and legacy Supernus holders own a minority position in a business whose largest product serves opioid use disorder, a category with its own reimbursement and legal history. Trailing EPS on Yahoo's basis is ~-$0.76 even though trailing net income is ~$450 million, a sign that merger accounting is still distorting per-share figures, so the ~7x forward multiple on 2027 consensus rests on estimates of a business that has not yet reported a full combined quarter. Pipeline outcomes have disappointed before, including the SPN-820 miss in treatment-resistant depression in early 2025, and SPN-817 and SPN-820 remain in Phase 2b. Since the close the near-term risk sits with the combined company, and the shares have slid ~15% in the month to November 20, 2026 and ~19% over three months as the market prices the more leveraged pairing.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell COLL or SUPN; figures are approximate and dated (as of November 2026). Verify current data before investing.